ES2727577T5 - Pharmaceutical composition containing an anti-nucleating agent - Google Patents

Pharmaceutical composition containing an anti-nucleating agent Download PDF

Info

Publication number
ES2727577T5
ES2727577T5 ES16198994T ES16198994T ES2727577T5 ES 2727577 T5 ES2727577 T5 ES 2727577T5 ES 16198994 T ES16198994 T ES 16198994T ES 16198994 T ES16198994 T ES 16198994T ES 2727577 T5 ES2727577 T5 ES 2727577T5
Authority
ES
Spain
Prior art keywords
compound
salt
weight
drug
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES16198994T
Other languages
English (en)
Spanish (es)
Other versions
ES2727577T3 (es
Inventor
Laura Artino
Maria Cruanes
Wei Xu
Honggang Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36565788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2727577(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of ES2727577T3 publication Critical patent/ES2727577T3/es
Application granted granted Critical
Publication of ES2727577T5 publication Critical patent/ES2727577T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16198994T 2004-12-03 2005-12-02 Pharmaceutical composition containing an anti-nucleating agent Expired - Lifetime ES2727577T5 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63285904P 2004-12-03 2004-12-03

Publications (2)

Publication Number Publication Date
ES2727577T3 ES2727577T3 (es) 2019-10-17
ES2727577T5 true ES2727577T5 (en) 2025-04-02

Family

ID=36565788

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16198994T Expired - Lifetime ES2727577T5 (en) 2004-12-03 2005-12-02 Pharmaceutical composition containing an anti-nucleating agent

Country Status (9)

Country Link
US (1) US8771733B2 (enExample)
EP (2) EP3165220B2 (enExample)
JP (3) JP2008521929A (enExample)
CN (1) CN101068533B (enExample)
AU (1) AU2005311714B2 (enExample)
CA (1) CA2588465C (enExample)
ES (1) ES2727577T5 (enExample)
TR (1) TR201907729T4 (enExample)
WO (1) WO2006060681A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007006637A (es) * 2004-12-03 2007-06-19 Merck & Co Inc Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
TR201907729T4 (tr) 2004-12-03 2019-06-21 Merck Sharp & Dohme Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.
JP5228488B2 (ja) * 2004-12-03 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション 放出速度調節組成物を含有しているカルボキサミドｈｉｖインテグラーゼ阻害薬の医薬配合物
RU2420538C2 (ru) * 2006-10-27 2011-06-10 Пфайзер Продактс Инк. Жесткие капсулы из гидроксипропилметилцеллюлозы и способ их получения
CN101197832B (zh) * 2007-12-13 2012-01-25 华为技术有限公司 一种实现iptv业务的方法、系统、装置
ES2549387T3 (es) 2009-06-02 2015-10-27 Hetero Research Foundation Procedimiento de preparación de raltegravir potásico amorfo
ES2898348T3 (es) 2009-10-26 2022-03-07 Merck Sharp & Dohme Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
RU2012146517A (ru) * 2010-04-01 2014-05-10 Тева Фармасьютикал Индастриз Лтд. Соли ральтегравира и их кристаллические формы
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP3745856B1 (en) 2018-02-02 2025-11-19 The General Hospital Corporation Methods of supercooling aqueous samples
US12465565B2 (en) 2020-01-23 2025-11-11 Lupin Limited Pharmaceutical compositions of raltegravir
US20230277587A1 (en) * 2022-03-03 2023-09-07 Dermacisen, S.A. Food supplement for oral administration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
CA2019324C (en) * 1989-07-10 1996-08-20 Robert L. Jerzewski Fosinopril tablet formulations
JP2707023B2 (ja) * 1992-07-01 1998-01-28 株式会社大塚製薬工場 経口吸収用製剤
WO2000018384A2 (en) 1998-09-28 2000-04-06 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
PL348596A1 (en) * 1998-12-25 2002-06-03 Shionogi & Co Aromatic heterocycle compounds having hiv integrase inhibiting activities
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
US7276510B2 (en) * 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
SI1441734T1 (sl) * 2001-10-26 2007-08-31 Angeletti P Ist Richerche Bio Dihidropirimidin karboksamidni inhibitorji HIV-integraze
DE60209381T2 (de) * 2001-10-26 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
US20050165000A1 (en) † 2002-04-10 2005-07-28 Robertson Sandra K. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
BR0317749A (pt) 2002-12-27 2005-11-22 Angeletti P Ist Richerche Bio Composto, composição farmacêutica, e, uso de um composto
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
TR201907729T4 (tr) † 2004-12-03 2019-06-21 Merck Sharp & Dohme Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.
JP5228488B2 (ja) † 2004-12-03 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション 放出速度調節組成物を含有しているカルボキサミドｈｉｖインテグラーゼ阻害薬の医薬配合物
MX2007006637A (es) * 2004-12-03 2007-06-19 Merck & Co Inc Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
US9968607B2 (en) † 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof

Also Published As

Publication number Publication date
CN101068533B (zh) 2011-04-27
WO2006060681A2 (en) 2006-06-08
EP1819323B1 (en) 2016-11-16
JP2013063999A (ja) 2013-04-11
EP1819323A4 (en) 2012-07-18
CA2588465C (en) 2013-10-01
CA2588465A1 (en) 2006-06-08
EP3165220B1 (en) 2019-04-03
JP2012184250A (ja) 2012-09-27
CN101068533A (zh) 2007-11-07
US20080118559A1 (en) 2008-05-22
EP3165220A1 (en) 2017-05-10
AU2005311714A1 (en) 2006-06-08
ES2727577T3 (es) 2019-10-17
EP1819323B2 (en) 2023-03-22
EP3165220B2 (en) 2024-11-13
EP1819323A2 (en) 2007-08-22
WO2006060681A3 (en) 2006-10-12
US8771733B2 (en) 2014-07-08
AU2005311714B2 (en) 2010-09-30
TR201907729T4 (tr) 2019-06-21
JP2008521929A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
ES2957912T3 (es) Composiciones farmacéuticas que comprenden nilotinib
JP2012184250A (ja) 抗核形成剤を含有する医薬組成物
IL183615A (en) Pharmaceutical formulation of HIV carboxamide amide-containing inhibitors containing the controlled-release composition
EP2589384A1 (en) New Pharmaceutical Compositions for the Treatment of Hyper-Proliferative Disorders
US20130245061A1 (en) Pharmaceutical compositions
WO2013147135A1 (ja) 放出制御医薬組成物
RU2830564C2 (ru) Фармацевтическая композиция для перорального введения, содержащая энзалутамид
HK40070844B (en) Pharmaceutical compositions comprising nilotinib
HK1133193B (en) Pharmaceutical compositions comprising nilotinib or its salt